Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- XENE
- Price
- 33.44
- Stock movement up
- +2.04 (6.50%)
- Company name
- Xenon Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.55B
- Ent value
- 2.50B
- Price/Sales
- 473.88
- Price/Book
- 3.20
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 8.96%
- 1 year return
- -22.18%
- 3 year return
- -0.84%
- 5 year return
- 21.33%
- 10 year return
- 7.00%
Last updated: 2025-04-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
XENE does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 473.88 |
| Price to Book | 3.20 |
| EV to Sales | 464.67 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 76.24M |
| EPS (TTM) | -2.74 |
| FCF per share (TTM) | -2.09 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.38M |
| Gross profit (TTM) | 3.27M |
| Operating income (TTM) | -255.52M |
| Net income (TTM) | -213.39M |
| EPS (TTM) | -2.74 |
| EPS (1y forward) | -3.50 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 60.80% |
| Operating margin (TTM) | -4749.37% |
| Profit margin (TTM) | -3966.32% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 87.62M |
| Net receivables | 938.00K |
| Total current assets | 659.64M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 835.90M |
| Accounts payable | 5.42M |
| Short/Current long term debt | 9.79M |
| Total current liabilities | 29.70M |
| Total liabilities | 38.09M |
| Shareholder's equity | 797.81M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -160.69M |
| Capital expenditures (TTM) | 2.30M |
| Free cash flow (TTM) | -162.99M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -26.75% |
| Return on Assets | -25.53% |
| Return on Invested Capital | -26.70% |
| Cash Return on Invested Capital | -20.39% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 31.91 |
| Daily high | 33.70 |
| Daily low | 31.20 |
| Daily Volume | 848K |
| All-time high | 50.04 |
| 1y analyst estimate | 57.19 |
| Beta | 1.25 |
| EPS (TTM) | -2.74 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 4 Jun 2025 |
Downside potential
Loading...
Downside potential data
| XENE | S&P500 | |
| Current price drop from All-time high | -33.17% | -12.04% |
| Highest price drop | -90.43% | -56.47% |
| Date of highest drop | 16 Nov 2017 | 9 Mar 2009 |
| Avg drop from high | -41.51% | -11.07% |
| Avg time to new high | 75 days | 12 days |
| Max time to new high | 1696 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.55B
Marketcap category
Mid-cap
Description
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Employees
251
Website
Investor relations
-
SEC filings
CEO
Simon Neil Pimstone
Country
USA
City
Burnaby
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page